OncoMatch/Clinical Trials/NCT06514768
JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)
Is NCT06514768 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies JY231 for b-cell acute lymphoblastic leukemia (b-all).
Treatment: JY231 — Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of B-cell acute lymphoblastic leukemia (B-ALL)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 positive expression
Performance status
ECOG 0–3(Limited self-care)
Demographics
Prior therapy
Cannot have received: CD19-targeted therapy
Previously received treatment targeting CD19
Cannot have received: autologous hematopoietic stem cell transplantation
Received autologous hematopoietic stem cell transplantation within 6 weeks
Cannot have received: experimental drug
Received other experimental drug treatments within the past 3 months
Lab requirements
Blood counts
ALC ≥ 0.5E9/L, PLT > 30E9/L, Hb > 80g/L
Kidney function
Creatinine clearance rate >30 mL/min
Liver function
ALT and AST ≤ 2.5 × ULN, which can be relaxed to ≤ 5 × ULN for patients with liver invasion; Total serum bilirubin < 34 μMol/L
Cardiac function
Cardiac ejection fraction (EF) ≥ 40%, without pericardial effusion and significant arrhythmia; Indoor oxygen saturation (SpO2) ≥ 92%
The patient has good liver, kidney, heart, and lung functions: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × upper limit of normal(ULN), which can be relaxed to ≤ 5 × ULN for patients with liver invasion; Total serum bilirubin < 34 μMol/L; Creatinine clearance rate>30 mL/min; Cardiac ejection fraction (EF) ≥ 40%, without pericardial effusion and significant arrhythmia; Indoor oxygen saturation (SpO2) ≥ 92%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06514768 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CD19-targeted therapy, autologous hematopoietic stem cell transplantation, experimental drug disqualifies patients from enrollment.
Does this trial require CD19?
Yes, CD19 positive expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages